Last reviewed · How we verify
Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
NA trial testing PedsBP CDS in Hypertension in 41,054 participants. Completed in 31 July 2025.
| Lead sponsor | HealthPartners Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 41,054 |
| Start date | 1 August 2022 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across United States |
HealthPartners Institute
Adults 6 to 17, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of participants with blood pressure re-measurement at the index primary care encounter, among those with a first elevated blood pressure at the index primary care encounter.
| Group | Value | 95% CI |
|---|---|---|
| Control | 245 | |
| Low-Intensity Implementation | 829 | |
| High-Intensity Implementation | 1813 |
Number of participants with recognition of hypertension within 6 months of meeting incident hypertension criteria. Clinical recognition of hypertension was based on having a diagnosis of elevated BP (R03) or hypertension (I10, I15) or by having these diagnoses added to the problem list.
| Group | Value | 95% CI |
|---|---|---|
| Control | 22 | |
| Low-Intensity Implementation | 37 | |
| High-Intensity Implementation | 121 |
Time frame: Safety events were passively monitored every 6 months during the 18-month intervention period and 12-month follow up period. Patients were monitored for events occurring within 6 months of index visit newly meeting stage 1 and 2 hypertension criteria.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
| Reaction | System | Control | Low-Intensity Implementation | High-Intensity Implementat… |
|---|---|---|---|---|
| Stroke | Vascular disorders | — | — | — |
| Transient Ischemic Attack | Vascular disorders | — | — | — |
| Acute Renal Failure | Renal and urinary disorders | — | — | — |
| Hypertensive Crisis | Vascular disorders | — | — | — |
| Reaction | System | Control | Low-Intensity Implementation | High-Intensity Implementat… |
|---|---|---|---|---|
| Hospitalization for any cause | General disorders | — | — | — |
| Echocardiogram conducted | Surgical and medical procedures | — | — | — |
| Order for anti-hypertensive medication | Vascular disorders | — | — | — |
| Renal Ultrasound Conducted | Surgical and medical procedures | — | — | — |
Most-reported serious reactions: Stroke, Transient Ischemic Attack, Acute Renal Failure, Hypertensive Crisis.
Data from ClinicalTrials.gov NCT05126082 adverse events section.
The goal of the PedsBP CDS research project is to adapt a previously tested web-based clinical decision support tool that appropriately identifies high blood pressure in youth for use in a primarily rural health system and compare approaches to CDS implementation in 45 primary care clinics treating children in 3 upper Midwest states. This project will advance implementation science and address a critical need for youth at risk for cardiovascular disease and with limited access to pediatric subspecialty care.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing